Ridgeback Biotherapeutics announces the launch of two phase II clinical trials to test the efficacy of EIDD 2801 as an anti-viral treatment for COVID-19.Merck Inc.
Ridgeback Biotherapeutics announces the launch of two Phase II clinical trials to test the efficacy of EIDD 2801 as an anti-viral treatment for COVID-19. Phase I trials recently… read more.